Thomas Leggett has sold stock and made no open-market buys since Sep 2020

Thomas (Tommy) Leggett is a corporate finance executive and Chief Financial Officer of Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on RNA-based medicines to upregulate protein expression in severe diseases.( Appointed CFO in April 2024, he oversees all aspects of the company’s financial strategy and operations and succeeded former CFO Stephen Tulipano.( As a named executive officer, Leggett’s role includes leading capital allocation, financing activities, and investor-facing financial communications for Stoke Therapeutics.(

Leggett brings more than two decades of experience as an investment banker and biotechnology finance leader, having secured financing for dozens of life science companies.( Before joining Stoke, he served as CFO at Affinia Therapeutics, Black Diamond Therapeutics—where he helped lead an $85 million Series C and a $231 million IPO—and Axcella Health.( Earlier in his career, he spent over a decade in healthcare investment banking at J.P. Morgan Securities, Lazard Frères & Company, and UBS Securities.( Leggett also serves on the board of directors of Clover Biopharmaceuticals and previously sat on the board of Research Alliance Corp. II.( He holds an MBA in Finance from the Wharton School of the University of Pennsylvania and a BA in Economics from Columbia University.(

Written by Perplexity from public sources.